表紙
市場調查報告書

全球癌症診斷藥市場:產品類型,用途,各地區 - 成長,趨勢,預測

Global Cancer Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 629138
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
Back to Top
全球癌症診斷藥市場:產品類型,用途,各地區 - 成長,趨勢,預測 Global Cancer Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年04月01日內容資訊: 英文 114 Pages
簡介

本報告提供全球乳癌治療市場相關調查,彙整市場概要和不同治療,各地區趨勢,及加入此市場的主要企業的簡介等資料。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 主要推論

第5章 市場概要

  • 目前市場方案
  • 波特五力分析

第6章 促進要素,阻礙要素,機會,課題分析

  • 推動市場的要素
  • 阻礙市場的要素
  • 機會
  • 主要課題

第7章 市場區隔

  • 各產品
    • 次世代定序
    • 微陣列
    • 原位雜合
    • PCR
    • 流式細胞技術
    • 免疫組織化學
    • MRI
    • CT
    • PET
    • 超音波
    • 切片檢查
    • 乳房X光攝影
  • 各用途
    • 大腸癌
    • 乳癌
    • 肺癌
    • 子宮頸癌
    • 腎臟癌
    • 肝癌
    • 胰臟癌
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第8章 競爭環境

  • 合併·收購分析
  • 協定,聯合,聯盟
  • 新產品上市

第9章 主要加入企業

  • Abbott
  • Qiagen
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.
  • GE Healthcare
  • Hologic Inc.
  • Illumina Inc
  • Philips Healthcare
  • Agilent Technologies Inc
  • 其他

第10章 市場未來

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 56148

Market Overview

Increase in the number of cancer cases and the rise in geriatric population are the major factors which are attributing for the growth of the Cancer Diagnostics market globally. As per the WHO statistics, cancer accounts for 13% of deaths globally every year, moreover, 70% increase in cancer incidences is anticipated over the next couple of decades and global geriatric population is anticipated to nearly double from 12% to 22% from 2015 to 2022. Furthermore, increase in the emergence of new technologies like biomarkers and point of care testing, inclination towards advanced less-painful and way more efficient tests from conventional tests, improved healthcare expenditure, growing awareness, and increased government support are the few more factors which are boosting the growth of the Cancer Diagnostics market globally. However, stringent regulatory framework, lack of universal health coverage, expensive diagnostic procedures, prolonged time of approvals for product launching and cost containment measures are the few factors restraining the growth of Cancer Diagnostics market globally.

Scope of the Report

Cancer is a complex disease that impacts every patient differently. Comprehensive and personalized treatment starts with an accurate, thorough diagnosis that includes radiology, pathology, genetics and advanced genomic testing. Sophisticated tests and procedures are used to measure the stage and progression of the disease and identify the tumor's type, size, and location.

Cancer diagnosis begins with a thorough physical exam and a complete medical history. Laboratory studies are performed to detect abnormalities that may indicate cancer. When a tumor is suspected, imaging tests help doctors to determine cancer's location and size. To confirm the diagnosis of most cancers, a biopsy needs to be performed in which a tissue sample is removed from the suspected tumor and studied under a microscope to check for cancer cells. If the diagnosis is positive (cancer is present), other tests are performed to provide specific information about cancer. If the initial diagnosis is positive for cancer and symptoms persist, further tests may be needed and the further treatment is started.

Key Market Trends

Imaging Test is expected to dominate the Cancer Diagnostics Market

The most commonly used screening test for cancer is diagnostic imaging tests. The different kinds of imaging techniques for cancer detection are Imaging (Radiology) Tests for Cancer, CT Scans, MRI, Nuclear Medicine Scans, Ultrasound, Mammograms, X-rays and Other Radiographic Tests and are considered as the most reliable ones. Factors that are responsible for the growth of this segment include the increasing awareness about the early detection of cancer, the growing incidence of various types of cancer, and the increasing government initiatives and support. Mammograms are the most widely used tests to diagnose cancers. Mammography is the gold standard technique used to screen breast cancer, governments and other healthcare organizations around the world are taking initiatives to provide women, between the ages of 50 and 75, access to mammography screening. As per the Breastcancer.org, about one in eight US women (about 12.4%) will develop invasive breast cancer over the course of their lifetime. In 2018, an estimated 266,120 new cases of invasive breast cancer are anticipated to be diagnosed in women only in the United States, along with 63,960 new cases of non-invasive breast cancer.

The Asia Pacific is anticipated to grow rapidly in the global Cancer Diagnostics market

Asia-Pacific is expected to record a substantial growth over the forecast period, due to the existence of a large patient pool, availability of skilled professionals at a reasonable cost, and a distinct regulatory framework supporting accelerated product approvals and growing economic developments in countries like China and India and improved healthcare infrastructure. According to "India Against Cancer" report, total deaths due to cancer in 2018 in India are 7, 84,821 out of which 4,13,519 are Men and 3,71,302 are Women. Market players in the APAC region are involved in partnerships and agreements to enhance the market growth in Cancer Diagnostics. For instance, In April 2019, Halifax signs an exclusive agreement with Genecast to make Immunoscore® available in China. In June 2017, Agilent Technologies Inc. and Agendia, Inc. have entered into an agreement to expand their relationship to include the development of an RNA-Seq kit version of Agendia's currently marketed MammaPrint and BluePrint tests.

Competitive Landscape

The global Cancer Diagnostics market is highly fragmented with the presence of a large number of local and international players. Key players are adopting different growth strategies to enhance their marke presence such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. For instance, In November 2018, Belgian molecular diagnostics company Biocartis Group entered into an agreement with AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe. In March 2019, NeoGenomics Laboratories, Inc. announced the launch of "Ventana PD-L1 (SP142) Assay" testing for tumor tissue testing in patients with a triple negative subtype of breast cancer. The test recently approved by the FDA for patients who might respond to "TECENTRIQ", an immune checkpoint inhibitor in combination with chemotherapy. In March 2017, Biodesix, Inc. and Progenetics LTD entered into an international agreement where Progenetics will market and distribute kits for Biodesix's GeneStrat® and VeriStrat® liquid biopsy tests for patients with non-small cell lung cancer (NSCLC). Both tests are now available for clinical use in Israel.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Ease of Cancer Diagnosis
    • 4.2.2 ncreasing Healthcare Expenditure
    • 4.2.3 Emergence of New Technologies such as Biomarkers and Point of Care Testing
  • 4.3 Market Restraints
    • 4.3.1 Limited Use in the Emerging Markets
    • 4.3.2 Expensive Diagnostic Procedures
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Diagnotic Type
    • 5.1.1 Diagnostic Imaging Tests
    • 5.1.2 Biopsy and Cytology Tests
    • 5.1.3 Tumor Biomarkers
    • 5.1.4 Others
  • 5.2 Application
    • 5.2.1 Breast Cancer
    • 5.2.2 Lung Cancer
    • 5.2.3 Cervical Cancer
    • 5.2.4 Kidney Cancer
    • 5.2.5 Liver Cancer
    • 5.2.6 Pancreatic Cancer
    • 5.2.7 Ovarian Cancer
    • 5.2.8 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott
    • 6.1.2 Qiagen
    • 6.1.3 F. Hoffmann-La Roche Ltd
    • 6.1.4 Siemens Healthcare GmbH
    • 6.1.5 Thermo Fisher Scientific Inc.
    • 6.1.6 GE Healthcare
    • 6.1.7 Hologic Inc.
    • 6.1.8 Illumina Inc
    • 6.1.9 Philips Healthcare
    • 6.1.10 Agilent Technologies Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top